Effect of Mitotane on Male Gonadal Function.
adrenocortical carcinoma
male gonadal function
mitotane
testis
testosterone
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jun 2023
18 Jun 2023
Historique:
received:
03
05
2023
revised:
02
06
2023
accepted:
13
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Clinical evidence has shown frequent hypogonadism following mitotane (MTT) treatment in male patients with adrenocortical carcinoma. This study aimed to evaluate the impact of MTT on male gonadal function. Morphological analysis of testes and testosterone assays were performed on adult CD1 MTT-treated and untreated mice. The expression of key genes involved in interstitial and tubular compartments was studied by real-time PCR. Moreover, quantitative and qualitative analysis of spermatozoa was performed. Several degrees of damage to the testes and a significant testosterone reduction in MTT-treated mice were observed. A significant decline in MTT negatively affects the male reproductive system, including changes in the morphology of testicular tissue and reductions in sperm concentration and quality.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical evidence has shown frequent hypogonadism following mitotane (MTT) treatment in male patients with adrenocortical carcinoma. This study aimed to evaluate the impact of MTT on male gonadal function.
METHODS
METHODS
Morphological analysis of testes and testosterone assays were performed on adult CD1 MTT-treated and untreated mice. The expression of key genes involved in interstitial and tubular compartments was studied by real-time PCR. Moreover, quantitative and qualitative analysis of spermatozoa was performed.
RESULTS
RESULTS
Several degrees of damage to the testes and a significant testosterone reduction in MTT-treated mice were observed. A significant decline in
CONCLUSION
CONCLUSIONS
MTT negatively affects the male reproductive system, including changes in the morphology of testicular tissue and reductions in sperm concentration and quality.
Identifiants
pubmed: 37370841
pii: cancers15123234
doi: 10.3390/cancers15123234
pmc: PMC10296642
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Sapienza Progetti Ateneo e PRIN 2017
ID : 2017TK7Z8L
Références
J Clin Endocrinol Metab. 2006 Jun;91(6):2165-70
pubmed: 16551731
Biol Reprod. 2010 Jun;82(6):1139-50
pubmed: 20164437
J Endocrinol Invest. 2016 Jan;39(1):103-21
pubmed: 26165270
Cancers (Basel). 2019 Nov 09;11(11):
pubmed: 31717612
Int J Mol Sci. 2013 Sep 02;14(9):17926-42
pubmed: 24002028
Reprod Toxicol. 2014 Jun;45:71-6
pubmed: 24486453
Endocr Relat Cancer. 2008 Dec;15(4):1043-53
pubmed: 18824557
J Endocrinol. 2010 May;205(2):117-31
pubmed: 20144980
Anim Reprod Sci. 2008 Apr;105(1-2):144-57
pubmed: 18155861
PLoS One. 2021 Mar 25;16(3):e0240278
pubmed: 33764986
J Endocrinol. 2017 Jul;234(1):29-39
pubmed: 28450646
Semin Cell Dev Biol. 2014 Jun;30:2-13
pubmed: 24598768
Cancers (Basel). 2020 Sep 14;12(9):
pubmed: 32937772
Hum Exp Toxicol. 2001 Aug;20(8):393-7
pubmed: 11727789
Horm Behav. 1981 Sep;15(3):238-45
pubmed: 7298026
Cell Biol Toxicol. 1998 Mar;14(2):111-20
pubmed: 9553722
Clin Endocrinol (Oxf). 2021 Feb;94(2):141-149
pubmed: 32996176
Eur J Endocrinol. 2012 Oct;167(4):473-81
pubmed: 22815335
J Clin Endocrinol Metab. 2013 Jan;98(1):161-71
pubmed: 23162091
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101380
pubmed: 32165101
Front Endocrinol (Lausanne). 2023 Apr 05;14:1128061
pubmed: 37077359
Fertil Steril. 2013 Jan;99(1):132-139
pubmed: 23040523
J Toxicol Clin Toxicol. 1987;25(6):463-72
pubmed: 3441014
J Androl. 1994 Jul-Aug;15(4):273-6
pubmed: 7982794
J Clin Endocrinol Metab. 2021 Jan 1;106(1):16-25
pubmed: 33118025